FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2536341760> ?p ?o ?g. }

• W2536341760 abstract "Abstract Background: Chronic lymphocytic leukemia (CLL) is a disease with unpredictable natural history in stage A patients (pts). Recently, It has been demonstrated that ZAP-70 and IgVH mutational status are powerful biological prognostic factors and we previously reported that the doubling time of soluble CD23 (sCD23DT) is a prognostic factor for progression of disease in untreated stage A CLL. Therefore we prospectively evaluated ZAP-70 protein expression and IgVH mutational status in untreated stage A B-CLL pts and correlated these markers with sCD23DT. Methods: sCD23 level was evaluated by commercially available enzyme-linked immunosorbent assay (ELISA). ZAP-70 expression is determined in leukemic cells by flow cytometry, and positive expression was defined as &gt;20% positive cells. When tests became available, ZAP-70 gene expression and IgVH mutational status were also evaluated in all pts included in the sCD23 study. Results: 47 pts with untreated stage A B-CLL are evaluable for the sCD23DT. ZAP-70 and mutational status were evaluated in 34pts. Median age was 62 (42–82) years. The median follow-up was 58 (16–129) months. The sCD23DT was clearly associated with progression to upper stages requiring a treatment: median time to progression was 25 Mos in pts with sCD23 DT inferior to one year comparing to 141 months in pts with sCD23 DT superior to one year (p&lt;0.0001). Time to progression in the group of pts with positive ZAP-70 expression was 19.1 mos comparing to 86.1 mos in ZAP-70 negative group (p=0.0001) Time to progression to treatment for pts with unmutated IgVH was 15,9 mos and 86,1 mos for pts with mutated status (p&lt;0.001). In the group of pts with ZAP-70 positive expression 6pts (67%) needed a treatment. Among ZAP-70+ and sCD23DT&lt; 1 year pts, 100% (6/6) required a treatment. For pts with positive ZAP-70 and a sCD23DT superior to one year, 100% (3/3) of pts do not need a treatment (p=0.0188). In the group of good prognosis pts with negative ZAP-70, 24% (6/25) of the pts required a treatment, median time to progression for these pts was 66,6 mos. in the ZAP-70 negative pts population, 3/25 (12%) have a sCD23DT&lt;1 year and 2 of these pts required a treatment for disease progression. Among the pts with indolent progression, negative ZAP-70 and who do not need a treatment, 96 % of the pts have a sCD23DT superior to one year. In the group of pts with unmutated status (n=8), 88% of the pts needed a treatment and all the pts had a sCD23DT inferior to one year, the only pts who did not required a treatment had a sCD23DT superior to one year. Among patients with mutated IgVH 73% did not require a treatment and 95% of those pts had a sCD23DT superior to one year. Among the mutated pts who progressed to treatment 42% had a sCD23DT inferior to one year, the 58% of treated pts with sCD23DT superior to one year and unmutated status had a median time to progression of 68 mos. In conclusion, CLL patients can be divided into different risk categories according to sCD23 serial determinations. sCD23DT is an additional important prognostic marker for disease progression even in ZAP-70 positive patients." @default.
• W2536341760 created "2016-10-28" @default.
• W2536341760 creator A5004525684 @default.
• W2536341760 creator A5036703667 @default.
• W2536341760 creator A5038795221 @default.
• W2536341760 creator A5053031492 @default.
• W2536341760 creator A5074992319 @default.
• W2536341760 date "2005-11-16" @default.
• W2536341760 modified "2023-09-28" @default.
• W2536341760 title "Doubling Time of Soluble CD23 Is an Additional Prognostic Factor in ZAP 70 Positive CLL Patients." @default.
• W2536341760 doi "https://doi.org/10.1182/blood.v106.11.5020.5020" @default.
• W2536341760 hasPublicationYear "2005" @default.
• W2536341760 type Work @default.
• W2536341760 sameAs 2536341760 @default.
• W2536341760 citedByCount "0" @default.
• W2536341760 crossrefType "journal-article" @default.
• W2536341760 hasAuthorship W2536341760A5004525684 @default.
• W2536341760 hasAuthorship W2536341760A5036703667 @default.
• W2536341760 hasAuthorship W2536341760A5038795221 @default.
• W2536341760 hasAuthorship W2536341760A5053031492 @default.
• W2536341760 hasAuthorship W2536341760A5074992319 @default.
• W2536341760 hasConcept C126322002 @default.
• W2536341760 hasConcept C141105273 @default.
• W2536341760 hasConcept C143998085 @default.
• W2536341760 hasConcept C146357865 @default.
• W2536341760 hasConcept C1491633281 @default.
• W2536341760 hasConcept C151730666 @default.
• W2536341760 hasConcept C159654299 @default.
• W2536341760 hasConcept C203014093 @default.
• W2536341760 hasConcept C2777938653 @default.
• W2536341760 hasConcept C2778461978 @default.
• W2536341760 hasConcept C34814297 @default.
• W2536341760 hasConcept C48900799 @default.
• W2536341760 hasConcept C54355233 @default.
• W2536341760 hasConcept C553184892 @default.
• W2536341760 hasConcept C71924100 @default.
• W2536341760 hasConcept C86803240 @default.
• W2536341760 hasConcept C90924648 @default.
• W2536341760 hasConceptScore W2536341760C126322002 @default.
• W2536341760 hasConceptScore W2536341760C141105273 @default.
• W2536341760 hasConceptScore W2536341760C143998085 @default.
• W2536341760 hasConceptScore W2536341760C146357865 @default.
• W2536341760 hasConceptScore W2536341760C1491633281 @default.
• W2536341760 hasConceptScore W2536341760C151730666 @default.
• W2536341760 hasConceptScore W2536341760C159654299 @default.
• W2536341760 hasConceptScore W2536341760C203014093 @default.
• W2536341760 hasConceptScore W2536341760C2777938653 @default.
• W2536341760 hasConceptScore W2536341760C2778461978 @default.
• W2536341760 hasConceptScore W2536341760C34814297 @default.
• W2536341760 hasConceptScore W2536341760C48900799 @default.
• W2536341760 hasConceptScore W2536341760C54355233 @default.
• W2536341760 hasConceptScore W2536341760C553184892 @default.
• W2536341760 hasConceptScore W2536341760C71924100 @default.
• W2536341760 hasConceptScore W2536341760C86803240 @default.
• W2536341760 hasConceptScore W2536341760C90924648 @default.
• W2536341760 hasLocation W25363417601 @default.
• W2536341760 hasOpenAccess W2536341760 @default.
• W2536341760 hasPrimaryLocation W25363417601 @default.
• W2536341760 hasRelatedWork W1499042964 @default.
• W2536341760 hasRelatedWork W1970296317 @default.
• W2536341760 hasRelatedWork W2060415116 @default.
• W2536341760 hasRelatedWork W2146361063 @default.
• W2536341760 hasRelatedWork W2261977783 @default.
• W2536341760 hasRelatedWork W2325177859 @default.
• W2536341760 hasRelatedWork W2356643487 @default.
• W2536341760 hasRelatedWork W2376037386 @default.
• W2536341760 hasRelatedWork W2999661765 @default.
• W2536341760 hasRelatedWork W2131918003 @default.
• W2536341760 isParatext "false" @default.
• W2536341760 isRetracted "false" @default.
• W2536341760 magId "2536341760" @default.
• W2536341760 workType "article" @default.